X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (36) 36
index medicus (27) 27
female (26) 26
male (26) 26
middle aged (26) 26
aged (21) 21
multiple myeloma - drug therapy (21) 21
oncology (20) 20
adult (18) 18
bortezomib (18) 18
hematology (16) 16
multiple myeloma (16) 16
treatment outcome (15) 15
aged, 80 and over (12) 12
survival (11) 11
antineoplastic agents - therapeutic use (10) 10
multiple myeloma - pathology (10) 10
lenalidomide (9) 9
multiple myeloma - therapy (9) 9
cancer (8) 8
multiple-myeloma (8) 8
recurrence (8) 8
thalidomide (8) 8
therapy (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
chemotherapy (7) 7
human necessities (7) 7
hygiene (7) 7
medical or veterinary science (7) 7
multiple myeloma - diagnosis (7) 7
preparations for medical, dental, or toilet purposes (7) 7
prognosis (7) 7
abridged index medicus (6) 6
agriculture (6) 6
animal husbandry (6) 6
article (6) 6
biocides, e.g. as disinfectants, as pesticides, as herbicides (6) 6
care and treatment (6) 6
dexamethasone (6) 6
fishing (6) 6
forestry (6) 6
hunting (6) 6
multiple myeloma - mortality (6) 6
myeloma (6) 6
pest repellants or attractants (6) 6
plant growth regulators (6) 6
preservation of bodies of humans or animals or plants or partsthereof (6) 6
trapping (6) 6
dose-response relationship, drug (5) 5
drug therapy (5) 5
expression (5) 5
multiple myeloma - complications (5) 5
neoplasm staging (5) 5
open-label (5) 5
peripheral neuropathy (5) 5
antineoplastic agents - adverse effects (4) 4
clinical trials as topic (4) 4
combination (4) 4
hematopoietic stem cell transplantation (4) 4
kaplan-meier estimate (4) 4
survival analysis (4) 4
survival rate (4) 4
t-lymphocytes - immunology (4) 4
thalidomide - analogs & derivatives (4) 4
thalidomide - therapeutic use (4) 4
antigens, neoplasm - immunology (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
boronic acids - therapeutic use (3) 3
cells (3) 3
clinical-features (3) 3
dexamethasone - administration & dosage (3) 3
drug administration schedule (3) 3
induction (3) 3
lenalidomide plus dexamethasone (3) 3
medicine, general & internal (3) 3
monoclonal gammopathy (3) 3
multiple myeloma - immunology (3) 3
multiple myeloma - metabolism (3) 3
patients (3) 3
proteasome inhibitors - therapeutic use (3) 3
pyrazines - therapeutic use (3) 3
specific therapeutic activity of chemical compounds ormedicinal preparations (3) 3
stem cell transplantation (3) 3
thalidomide - administration & dosage (3) 3
thalidomide - adverse effects (3) 3
time factors (3) 3
transplantation (3) 3
transplantation, autologous (3) 3
trial (3) 3
adoptive transfer (2) 2
antineoplastic agents - pharmacokinetics (2) 2
apoptosis (2) 2
biochemistry & molecular biology (2) 2
bisphosphonates (2) 2
bone (2) 2
bone-marrow transplantation (2) 2
boronic acids - adverse effects (2) 2
cancer-testis antigens (2) 2
carfilzomib (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2085 - 2085
Abstract Background: BKV HC is a well-known complication following allo-SCT. Supportive care with bladder irrigation and blood transfusions were the only... 
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, p. 575
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 490 - 490
Abstract BACKGROUND: Immunotherapy in MM is emerging as an effective modality in therapy of MM with the approval of several monoclonal antibodies and... 
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2015, Volume 21, Issue 8, pp. 914 - 921
Journal Article
Blood, ISSN 0006-4971, 06/2006, Volume 107, Issue 12, pp. 4973 - 4974
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5750 - 5750
Abstract Background: The role of metabolism in outcomes of cancer patients is under investigation. A higher body mass index (BMI) substantially increases the... 
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 11/2017, Volume 31, Issue 11, pp. 2443 - 2448
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2010, Volume 28, Issue 18, pp. 3015 - 3022
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 2118 - 2118
Abstract Marizomib, a natural marine product, is an irreversible proteasome inhibitor (PI) that has distinct advantages over the currently approved PIs in that... 
Journal Article
Leukemia & lymphoma, ISSN 1042-8194, 07/2019, pp. 1 - 4
Journal Article
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 02/2010, Volume 8, Issue 1, pp. S21 - S27
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4220 - 4220
Abstract Introduction: MRZ is a novel, irreversible, proteasome inhibitor (PI) under clinical development for the treatment of relapsed and refractory multiple... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 5507 - 5507
Abstract Background: P is used in combination with G-CSF to improve the mobilization of peripheral blood hematopoietic stem cells in poor mobilizers. Limited... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 506 - 506
Abstract BACKGROUND: Several recent studies have linked the interactions of programmed death 1 (PD-1) receptor and its ligand (PD-L1) to immunologic control of... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.